Advertisement
Swanson has over 30 years of experience in finance and accounting,including 17 years of CFO-level experience in life sciences and specialtypharmaceutical companies. Prior to joining Amira, Swanson was the CFO ofPrometheus Laboratories Inc., a privately-held specialty pharmaceuticalcompany which sells both pharmaceutical products and diagnostic testingservices for gastrointestinal diseases and disorders. During his time atPrometheus, Swanson led several financings totaling over $200 million dollarsand, most recently, led the filing of a registration statement for Prometheus'initial public offering. Prior to Prometheus, Swanson was the CFO of AdvancedTissue Sciences, Inc. where his responsibilities included the financing ofthis publicly-held, life sciences company. Swanson is a Certified PublicAccountant and holds an MBA from the University of Southern California.
Advertisement
"Mike's track record in the pharmaceutical industry speaks for itself, andI look forward to partnering closely with him as we chart a course for thecompany. His addition further enriches an already diverse and strongmanagement team," said Bob Baltera, Chief Executive Officer, Amira.
"I am truly excited to be working with the proven group of drug hunters atAmira," said Swanson. "I believe I will be able to provide the financialexpertise and support required on this fascinating journey of drug discoveryand development."
About Amira
Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is asmall molecule pharmaceutical company focused on the discovery and earlydevelopment of compounds to treat inflammatory disease linked to theeicosanoid pathway. Amira has strategic partnerships with GlaxoSmithKline andRoche in the area of inflammatory disease.
Amira combines the rigor of a big pharmaceutical company with theingenuity and energy of a small company, creating an environment for efficientand effective pre-clinical and clinical program decisions. Its scientificfounders have successfully worked together for more than a decade and werepivotal in the discovery of a number of inflammatory drugs, includingSingulair(R). The drug hunters at Amira are now actively leveraging theirhistory of success to create high-value compounds for the future. For moreinformation, visit http://www.amirapharm.com.
SOURCE Amira Pharmaceuticals
